From FB: MyEcheck 3 hrs · This 8-K filed March 11,

New Post Public Reply Private Reply Replies (0) Message Board
Whichever
From FB:


MyEcheck
3 hrs ·
This 8-K filed March 11, 2016 discloses a software license and agency agreement in Africa. The bank in Africa is a sub-licensee of MyECheck, under this software license issued to our Agent. The bank is contracted with the Agent, the Agent is contracted with us, with a pass through sub-license for whomever they sell our system.
Our revenue is split automatically at the time of the transaction, our percentage share of transaction fees go into a joint MyECheck/Agent account at the bank in real time.
The bank has contracted with a domestic company for the system (our Agent) and the software they have contracted for is ours.
https://www.sec.gov/…/161…/00011442041608...135_8k.htm
www.sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2016 MyECheck, Inc. (Exact name of registrant as specified in…
SEC.GOV

MyEcheck
MyEcheck Exhibit D of the software license enable sub-licensing to banks, here's the text of that agreement as filed with the SEC 3/11/2016 2. RIGHT TO USE. Licensee hereby grants to Customer a limited, non-exclusive, non-transferable (except as otherwise expressly set forth herein), license to install (in object code form only and only in accordance with the Documentation), maintain and run the MyECheck Social Banking Platform for the benefit of Customer’s end users. Customer may also make backup copies for disaster and recovery purposes as necessary and reasonable. Customer shall keep a record of each such backup copy and the location of its storage, and shall provide any and all such records to Licensee upon request. Customer must reproduce and include any and all copyright, proprietary and any other notices that appear on the original Software and any media therefore on any copies made by Customer.

3. RESTRICTIONS ON USE. Customer acknowledges that the Software, its structure, organization and Source Code, and the Documentation are the property and constitute valuable trade secrets of MyECheck and its suppliers. Customer agrees not to: (a) decompile or disassemble the Software, separate the Software into its component parts, or in any way attempt to reconstruct or discover any source code or algorithms of the Software by any means whatsoever; (b) remove any product identification, trademark, copyright, confidentiality, proprietary or other notice contained on or within the Software; (c) modify or create any derivative works from the Software or any part thereof, except to the extent that the Software provides for user-modifiable components (d) except as otherwise permitted herein, sell, sublicense, lease, rent, loan, assign, convey or otherwise transfer the Software or any component thereof; (e) otherwise copy or use the Software for any purpose or in any manner not expressly permitted in this Agreement; or (f) knowingly permit or encourage any third party to do any of the foregoing. All rights in and to the Software and Documentation not expressly granted to Customer in this Agreement are reserved by MyECheck, Licensee and their suppliers.

MyEcheck Inc (MYEC) Stock Research Links

MYEC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 13

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 10

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 13

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Credit Card Interest Rates and How to Manage Them

Updated Category News Views 352

Understanding Credit Card Interest Rates Recently, the average credit card interest rate has climbed to 22.63%, a notable rise from the previous average of 16.98%. The interest rate you face can vary widely based on the type of credit card and your individual credit profile. By understanding how credit card annual percentage rates (APR) work, you can potentially reduce...

Continue Reading
Hexaware Reports Strong Q3CY25 Performance with Revenue Rise

Updated Category News Views 183

Hexaware Technologies Financial Results Overview Hexaware Technologies (NSE: HEXT) has showcased impressive performance for the third quarter of calendar year 2025, with total revenue reaching USD 394.8 million. This figure marks a noteworthy increase of 5.5% year-over-year, showcasing the company's resilience and ability to navigate market challenges effectively....

Continue Reading
Alm. Brand A/S Reports Progress in Share Buybacks for 2024

Updated Category News Views 102

Overview of Alm. Brand A/S Share Buy-Back Program Alm. Brand A/S has kicked off an ambitious share buy-back program, looking to acquire shares totaling up to DKK 150 million. This initiative was officially announced earlier, providing insight into the year's financial strategy. Recent Transactions Under the Program During the week starting 9 September 2024 and ending on...

Continue Reading
NRx Pharmaceuticals Adjusts Release Date for Q2 Financials

Updated Category News Views 158

NRx Pharmaceuticals Announces Rescheduled Q2 2025 Financial Results Release NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) recently made an exciting announcement regarding the release of its second quarter 2025 financial results. The company has decided to delay the publication of these results to ensure a more comprehensive presentation for its stakeholders. This update comes...

Continue Reading
Top 5 Stocks to Watch for a Market Pullback Soon

Updated Category News Views 216

Understanding Market Pullbacks As major U.S. stock indices reached unprecedented levels recently, the optimism surrounding potential Federal Reserve rate cuts has driven prices higher. However, the surge seems excessive given the realistically anticipated modest decrease in rates. This opens a window for investors to reassess their portfolios, particularly those holdings...

Continue Reading